Literature DB >> 26725211

Total rectosigmoidectomy versus partial rectal resection in primary debulking surgery for advanced ovarian cancer.

F Plotti1, R Montera2, A Aloisi1, G Scaletta1, S Capriglione1, D Luvero1, C De Cicco Nardone1, S Basile3, P Benedetti Panici4, R Angioli1.   

Abstract

PURPOSE: To compare in a sample of Italian patients intraoperative, perioperative complications, Quality of Life (QoL), recurrence rate and overall survival of advanced ovarian cancer (AOC) patients according to the type of surgery performed on sigma-rectum, total rectosigmoid resection (TRR) versus partial rectosigmoid resection (PRR).
METHODS: From May 2004 to May 2010, consecutive patients affected by epithelial AOC (FIGO Stage III-IV) were assessed for this prospective case-control study, According to the type of colorectal surgery performed to approach rectosigmoid involvement, patients were allocated into Group A (TRR) and Group B (PRR). PRR was performed when the complete removal of disease led to a laceration <30-40% of intestinal wall circumference.
RESULTS: 82 and 72 patients were included in Group A and Group B respectively. Surgical outcomes were statistically similar except hospital stay which was significantly lower in the PRR group. There was not a statistically significant difference as regarding intra-operative, perioperative and postoperative complications, even if a higher rate of major complications were recorded in TRR. An improvement in QoL's scores has been recorded in PRR's group. There was not a statistically difference concerning the optimal debulking rate (92% and 96% respectively) and 5-year Overall Survival (48% and 52% respectively).
CONCLUSIONS: PRR seems to be feasible in over 40% of patients with advanced ovarian cancer and recto-sigmoid colon involvement. It is related to higher QoL and can be easily performed, without jeopardizing surgical radicality, in those cases in which conservative surgery at intestinal tract does not compromise residual tumor.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bowel surgery; Ovarian cancer; Primary debulking surgery; Quality of life

Mesh:

Year:  2015        PMID: 26725211     DOI: 10.1016/j.ejso.2015.12.001

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  6 in total

1.  Clinical Significance of Mesenteric Lymph Node Involvement in the Pattern of Liver Metastasis in Patients with Ovarian Cancer.

Authors:  Kana Tanaka; Yoshifumi Shimada; Koji Nishino; Kosuke Yoshihara; Masato Nakano; Hitoshi Kameyama; Takayuki Enomoto; Toshifumi Wakai
Journal:  Ann Surg Oncol       Date:  2021-04-05       Impact factor: 5.344

2.  Management of postoperative chylous ascites after surgery for ovarian cancer: a single-institution experience.

Authors:  Giuseppe Scaletta; Lorena Quagliozzi; Stefano Cianci; Virginia Vargiu; Maria Cristina Mele; Giovanni Scambia; Anna Fagotti
Journal:  Updates Surg       Date:  2019-04-20

3.  Partial Cystectomy for Atypical Isolated Recurrence of Ovarian Adenocarcinoma - A Case Report and Literature Review.

Authors:  Nicolae Bacalbasa; Irina Balescu
Journal:  In Vivo       Date:  2017 May-Jun       Impact factor: 2.155

4.  Clinical Phenotypes of Tumors Invading the Rectosigmoid Colon Affecting the Extent of Debulking Surgery and Survival in Advanced Ovarian Cancer.

Authors:  Soo Jin Park; Jaehee Mun; Eun Ji Lee; Sunwoo Park; Sang Youn Kim; Whasun Lim; Gwonhwa Song; Jae-Weon Kim; Seungmee Lee; Hee Seung Kim
Journal:  Front Oncol       Date:  2021-04-22       Impact factor: 6.244

5.  Rectosigmoid sparing en bloc pelvic resection for fixed ovarian tumors: Surgical technique and perioperative and oncologic outcomes.

Authors:  Ying Shan; Ying Jin; Yan Li; Yu Gu; Wei Wang; Lingya Pan
Journal:  Front Oncol       Date:  2022-08-22       Impact factor: 5.738

6.  Survival impact of low anterior resection in patients with epithelial ovarian cancer grossly confined to the pelvic cavity: a Korean multicenter study.

Authors:  Miseon Kim; Dong Hoon Suh; Jeong Yeol Park; E Sun Paik; Seungmee Lee; Kyung Jin Eoh; Joo Hyun Nam; Yoo Young Lee; Jae Weon Kim; Sunghoon Kim
Journal:  J Gynecol Oncol       Date:  2018-04-13       Impact factor: 4.401

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.